Lataa...
Dapagliflozin efficacy and safety: a perspective review
Type 2 diabetes mellitus is a prevalent, progressive disease with a need for innovative therapeutic agents to continue to advance disease management. Dapagliflozin is the second agent in a new class of oral antihyperglycemic drugs: sodium-glucose cotransporter 2 (SGLT2) inhibitors. SGLT2 is responsi...
Tallennettuna:
| Julkaisussa: | Ther Adv Drug Saf |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4232499/ https://ncbi.nlm.nih.gov/pubmed/25436106 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098614551938 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|